Chronic Lymphocytic Leukemia

Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.

Alexey V. Danilov, MD, PhD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

Alan P. Z. Skarbnik, MD, discusses treatment considerations in chronic lymphocytic leukemia.

Patients with chronic lymphocytic leukemia who are at an increased risk of failure on ibrutinib can be identified prior to treatment initiation using a 4-factor prognostic model and considered for a clinical trial.

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

The FDA has granted a fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of adult patients with chronic lymphocytic leukemia.

Alan P. Z. Skarbnik, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

Shuo Ma, MD, PhD, discusses the need to develop novel agents to treat patients with chronic lymphocytic leukemia who develop resistance to BTK inhibitors.

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.

Seema A. Bhat, MD, spotlights the advances that have been made with BTK inhibitors in chronic lymphocytic leukemia, shares emerging approaches under exploration, and forecasts where the field is headed.

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia and ongoing research in the space.

Erlene  Seymour, MD, discusses BTK inhibitors and how they have shifted the standard of care for the frontline treatment of patients with chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.

A fixed-duration of venetoclax plus rituximab led to sustained and durable responses in patients with relapsed/refractory chronic lymphocytic leukemia who achieved undetectable minimal residual disease.

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.

Christopher Pleyer, MD, discusses the next steps with ​the combination of ibrutinib and ​short-course fludarabine in previously untreated chronic lymphocytic leukemia.

Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.